A Systematic Literature Review of Magnetic Resonance Spectroscopy for the Characterization of Brain Tumors

References

1. ↵
   Sartor K. MR imaging of the brain: tumors. Eur Radiol 1999;9:1047–54

   CrossRefPubMed
2. ↵
   Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther 2003;2:497–507

   Abstract/FREE Full Text
3. ↵
   Barker PB. Fundamentals of MR spectroscopy. In: Gillard JH, Waldman AD, Barker PB, eds. Clinical MR Neuroimaging: Diffusion, Perfusion and Spectroscopy. 1st ed. Cambridge, UK: Cambridge University Press;2005
4. ↵
   New England Medical Center EPC. Magnetic resonance spectroscopy for brain tumors. In: EPC Technical Support of the CPTA Technology Assessment Program. Prepared for the Agency for Healthcare Research and Quality (AHRQ). Contract No. 290-02-0022 TO. Boston, MA;2003
5. ↵
   Technology Evaluation Center. Magnetic resonance spectroscopy for evaluation of suspected brain tumor. TEC Bull (Online) 2003;20:23–26

   PubMed
6. ↵
   Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25

   CrossRefPubMed
7. ↵
   Kelly S, Berry E, Roderick P, et al. The identification of bias in studies of the diagnostic performance of imaging modalities. Br J Radiol 1997;70:1028–35

   Abstract
8. ↵
   Kurt Rossman Laboratories, University of Chicago. PlotROC Excel macro [computer program]. Version 1.0.0. Chicago: University of Chicago.
9. ↵
   Devos A, Lukas L, Suykens JA, et al. Classification of brain tumours using short echo time 1H MR spectra. J Magn Reson 2004;170:164–75

   CrossRefPubMed
10. ↵
    Fountas KN, Kapsalaki EZ, Vogel RL, et al. Noninvasive histologic grading of solid astrocytomas using proton magnetic resonance spectroscopy. Stereotact Funct Neurosurg 2004;82:90–97

    CrossRefPubMed
11. ↵
    Herminghaus S, Dierks T, Pilatus U, et al. Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. J Neurosurg 2003;98:74–81

    PubMed
12. ↵
    Huang Y, Lisboa PJ, El-Deredy W. Tumour grading from magnetic resonance spectroscopy: a comparison of feature extraction with variable selection. Stat Med 2003;22:147–64

    PubMed
13. ↵
    Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–98

    Abstract/FREE Full Text
14. ↵
    Majos C, Alonso J, Aguilera C, et al. Adult primitive neuroectodermal tumor: proton MR spectroscopic findings with possible application for differential diagnosis. Radiology 2002;225:556–66

    PubMed
15. Majos C, Alonso J, Aguilera C, et al. Utility of proton MR spectroscopy in the diagnosis of radiologically atypical intracranial meningiomas. Neuroradiology 2003;45:129–36

    PubMed
16. ↵
    Majos C, Alonso J, Aguilera C, et al. Proton magnetic resonance spectroscopy ((1)H MRS) of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol 2003;13:582–91

    PubMed
17. ↵
    McKnight TR, von dem Bussche MH, Vigneron DB, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002;97:794–802

    PubMedWeb of Science
18. ↵
    Mishra AM, Gupta RK, Jaggi RS, et al. Role of diffusion-weighted imaging and in vivo proton magnetic resonance spectroscopy in the differential diagnosis of ring-enhancing intracranial cystic mass lesions. J Comput Assist Tomogr 2004;28:540–47

    CrossRefPubMed
19. ↵
    Moller-Hartmann W, Herminghaus S, Krings T, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002;44:371–81

    CrossRefPubMedWeb of Science
20. ↵
    Nafe R, Herminghaus S, Raab P, et al. Preoperative proton-MR spectroscopy of gliomas–correlation with quantitative nuclear morphology in surgical specimen. J Neurooncol 2003;63:233–45

    CrossRefPubMed
21. ↵
    Tate AR, Majos C, Moreno A, et al. Automated classification of short echo time in in vivo 1H brain tumor spectra: a multicenter study. Magn Reson Med 2003;49:29–36

    CrossRefPubMedWeb of Science
22. ↵
    Ando K, Ishikura R, Nagami Y, et al. [Usefulness of Cho/Cr ratio in proton MR spectroscopy for differentiating residual/recurrent glioma from non-neoplastic lesions]. Nippon Igaku Hoshasen Gakkai Zasshi 2004;64:121–26

    PubMed
23. ↵
    Gajewicz W, Papierz W, Szymczak W, et al. The use of proton MRS in the differential diagnosis of brain tumors and tumor-like processes. Med Sci Monit 2003;9:MT97–105

    PubMed
24. ↵
    Lukas L, Devos A, Suykens JA, et al. Brain tumor classification based on long echo proton MRS signals. Artif Intell Med 2004;31:73–89

    CrossRefPubMed
25. ↵
    Opstad KS, Murphy MM, Wilkins PR, et al. Differentiation of metastases from high-grade gliomas using short echo time 1H spectroscopy. J Magn Reson Imaging 2004;20:187–92

    CrossRefPubMedWeb of Science
26. ↵
    Plotkin M, Eisenacher J, Bruhn H, et al. 123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study. J Neurooncol 2004;70:49–58

    CrossRefPubMed
27. ↵
    Traber F, Block W, Flacke S, et al. [1H-MR Spectroscopy of brain tumors in the course of radiation therapy: use of fast spectroscopic imaging and single-voxel spectroscopy for diagnosing recurrence]. Rofo 2002;174:33–42

    CrossRefPubMed
28. ↵
    Astrakas LG, Zurakowski D, Tzika AA, et al. Noninvasive magnetic resonance spectroscopic imaging biomarkers to predict the clinical grade of pediatric brain tumors. Clin Cancer Res 2004;10:8220–28

    Abstract/FREE Full Text
29. ↵
    Lichy MP, Henze M, Plathow C, et al. [Metabolic imaging to follow stereotactic radiation of gliomas—the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT]. Rofo 2004;176:1114–21

    PubMed
30. ↵
    Majos C, Julia-Sape M, Alonso J, et al. Brain tumor classification by proton MR spectroscopy: comparison of diagnostic accuracy at short and long TE. AJNR Am J Neuroradiol 2004;25:1696–704

    Abstract/FREE Full Text
31. ↵
    Murphy M, Loosemore A, Clifton AG, et al. The contribution of proton magnetic resonance spectroscopy (1HMRS) to clinical brain tumour diagnosis. Br J Neurosurg 2002;16:329–34

    CrossRefPubMed
32. ↵
    Hall WA, Liu H, Maxwell RE, et al. Influence of 1.5-Tesla intraoperative MR imaging on surgical decision making. Acta Neurochir Suppl 2003;85:29–37

    PubMed
33. ↵
    Pirzkall A, Li X, Oh J, et al. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 2004;59:126–37

    CrossRefPubMedWeb of Science
34. ↵
    Pirzkall A, Nelson SJ, McKnight TR, et al. Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys 2002;53:1254–64

    CrossRefPubMedWeb of Science
35. ↵
    Adamson AJ, Rand SD, Prost RW, et al. Focal brain lesions: effect of single-voxel proton MR spectroscopic findings on treatment decisions. Radiology 1998;209:73–78

    PubMed
36. Butzen J, Prost R, Chetty V, et al. Discrimination between neoplastic and nonneoplastic brain lesions by use of proton MR spectroscopy: the limits of accuracy with a logistic regression model. AJNR Am J Neuroradiol 2000;21:1213–19

    Abstract/FREE Full Text
37. Hall WA, Martin A, Liu H, et al. Improving diagnostic yield in brain biopsy: coupling spectroscopic targeting with real-time needle placement. J Magn Reson Imaging 2001;13:12–15

    CrossRefPubMed
38. Kimura T, Sako K, Gotoh T, et al. In vivo single-voxel proton MR spectroscopy in brain lesions with ring-like enhancement. NMR Biomed 2001;14:339–49

    CrossRefPubMedWeb of Science
39. Lin A, Bluml S, Mamelak AN. Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors. J Neurooncol 1999;45:69–81

    CrossRefPubMed
40. Rand SD, Prost R, Haughton V, et al. Accuracy of single-voxel proton MR spectroscopy in distinguishing neoplastic from nonneoplastic brain lesions. AJNR Am J Neuroradiol 1997;18:1695–704

    Abstract
41. Roser W, Hagberg G, Mader I, et al. Assignment of glial brain tumors in humans by in vivo 1H-magnetic resonance spectroscopy and multidimensional metabolic classification. Magma 1997;5:179–83

    PubMed
42. Shukla-Dave A, Gupta RK, Roy R, et al. Prospective evaluation of in vivo proton MR spectroscopy in differentiation of similar appearing intracranial cystic lesions. Magn Reson Imaging 2001;19:103–10

    CrossRefPubMedWeb of Science
43. Tedeschi G, Lundbom N, Raman R, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997;87:516–24

    PubMedWeb of Science
44. Taylor JS, Langston JW, Reddick WE, et al. Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Int J Radiat Oncol Biol Phys 1996;36:1251–61

    CrossRefPubMed
45. ↵
    Wilken B, Dechent P, Herms J, et al. Quantitative proton magnetic resonance spectroscopy of focal brain lesions. Pediatr Neurol 2000;23:22–31

    PubMed
46. ↵
    Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882–93

    CrossRefPubMedWeb of Science
47. ↵
    Medina LS, Zurakowski D. Measurement variability and confidence intervals in medicine: why should radiologists care? Radiology 2003;226:297–301

    PubMed
48. ↵
    Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Radiology 2003;226:24–28

    CrossRefPubMedWeb of Science